摘要
目的探讨卵巢癌癌组织信号转导及转录活化因子2(STAT2)、肿瘤干细胞标记物CD24和CD44的表达与临床病理资料相关性。方法选取2017年1月至2020年2月我院病理科确诊的卵巢癌患者69例(卵巢癌组)、同期卵巢良性肿瘤患者32例(对照组),采用免疫组织化学法检测两组患者卵巢组织STAT2、CD24和CD44表达水平,并分析其表达水平与卵巢癌患者临床病理资料相关性。结果卵巢癌组患者卵巢组织中STAT2、CD24和CD44阳性表达率分别为68.12%、65.22%和73.91%,分别高于对照组的6.25%、12.50%和15.63%。卵巢癌患者卵巢组织中STAT2、CD24和CD44阳性表达率与年龄、病理类型无显著相关性,与病理分期、分化程度、淋巴结转移和腹水呈显著相关。CD24阳性患者1年生存率显著低于阴性患者。结论卵巢癌患者卵巢组织中STAT2、CD24和CD44表达水平明显升高,提示其可能参与卵巢癌的发生、发展和转移,CD24表达异常升高可能为预后不良的生物学指标。
Objective To explore the expression of signal transducer and activator of transcription 2(STAT2) and tumor stem cell markers CD24 and CD44 in ovarian cancer tissues and their correlation with the clinicopathological characteristics.Methods 69 patients diagnosed with ovarian cancer in the Department of Pathology of our hospital from January 2017 to February 2020 were selected as the ovarian cancer group,and 32 patients with benign ovarian tumors during the same period were selected as the benign control group.Immunohistochemistry was used to detect the expression level of STAT2,CD24 and CD44 in the ovarian tissues of two groups.Then we analyzed the correlation between their expression and the clinicopathological data of patients.Results The expression rates of STAT2,CD24 and CD44 in the ovarian cancer group were 68.12%,65.22% and 73.91%,respectively,higher than those in the control group,namely 6.25%,12.50% and 15.63%,respectively.The positive rates of STAT2,CD24 and CD44 in the ovarian lesions were not significantly related to age and pathological type but were significantly related to pathological stage,degree of differentiation,lymph node metastasis and ascites.The one-year survival rate of CD24 positive patients was significantly lower than CD24 negative patients.Conclusion The expression levels of STAT2,CD24 and CD44 in ovarian cancer tissues are significantly increased,which may be involved in its occurrence,development and metastasis.The elevated expression of CD24 may serve as a biological indicator of poor prognosis.
作者
梁运霞
张玉文
秦珍珠
王丹
豆颖
邱晓娣
Liang Yunxia;Zhang Yuwen;Qin Zhenzhu;Wang Dan;Dou Ying;Qiu Xiaodi(Department of Pathology,First People’s Hospital of Shangqiu City,Shangqiu 476100,China)
出处
《中国组织化学与细胞化学杂志》
CAS
CSCD
2021年第4期354-358,共5页
Chinese Journal of Histochemistry and Cytochemistry
